NeuroMetrix (NASDAQ:NURO – Get Free Report) released its quarterly earnings results on Tuesday. The medical device company reported ($0.75) earnings per share (EPS) for the quarter, RTT News reports. NeuroMetrix had a negative return on equity of 41.74% and a negative net margin of 181.04%. The company had revenue of $0.59 million for the quarter. During the same period in the previous year, the business posted ($1.66) EPS.
NeuroMetrix Trading Up 1.4 %
NURO traded up $0.05 during trading on Wednesday, hitting $3.60. The stock had a trading volume of 9,407 shares, compared to its average volume of 26,228. NeuroMetrix has a 12 month low of $2.66 and a 12 month high of $4.73. The company has a 50 day simple moving average of $4.04 and a 200-day simple moving average of $3.88. The firm has a market cap of $7.31 million, a PE ratio of -0.64 and a beta of 2.29.
Wall Street Analyst Weigh In
Separately, StockNews.com assumed coverage on NeuroMetrix in a report on Monday. They set a “sell” rating on the stock.
About NeuroMetrix
NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.
Read More
- Five stocks we like better than NeuroMetrix
- What is a Low P/E Ratio and What Does it Tell Investors?
- What a Trump Win Looks Like for the Market Now and Into 2025
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- Stock Market Upgrades: What Are They?
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for NeuroMetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix and related companies with MarketBeat.com's FREE daily email newsletter.